Screening for the HLA B5701 allele prior to initiation of abacavir therapy may help reduce the incidence of abacavir hypersensitivity reaction. Abacavir hypersensitivity reaction is a clinical ...

Screening prospectively for HLA-B*5701 — and avoiding abacavir use in those who test positive — reduces the incidence of hypersensitivity reaction to this NRTI. Abacavir is an attractive drug ...